FDA Makes History: First Approval for 20 Zyn Nicotine Pouches!

FDA's Groundbreaking Decision

The U.S. Food and Drug Administration (FDA) has made a significant move by authorizing the marketing of 20 Zyn nicotine pouch products through the premarket tobacco product application (PMTA) pathway. This marks the first time the agency has approved products typically known as nicotine pouches.

Details of the Approval

The FDA granted marketing orders for the following Zyn products, each available in two nicotine strengths (3 mg and 6 mg):

• Zyn Chill
• Zyn Cinnamon
• Zyn Citrus
• Zyn Coffee
• Zyn Cool Mint
• Zyn Menthol
• Zyn Peppermint
• Zyn Smooth
• Zyn Spearmint
• Zyn Wintergreen

These authorizations are specific to these products only and do not extend to other nicotine pouches or Zyn products.

Public Health Considerations

The FDA determined that these products meet the public health standard required by the 2009 Family Smoking Prevention and Tobacco Control Act. The evaluation concluded that the authorized Zyn products contain significantly lower amounts of harmful constituents compared to cigarettes and most smokeless tobacco products, indicating a lower risk of cancer and other serious health conditions.

Important Clarifications

It is crucial to note that this authorization does not imply that these tobacco products are safe, nor are they ‘FDA approved.’ The FDA is also monitoring youth risk associated with these products, stating that youth use of nicotine pouches remains low. According to the 2024 National Youth Tobacco Survey, only 1.8% of middle and high school students reported current use of nicotine pouches.

Responsible Marketing

Dr. Brian King, director of the FDA’s Center for Tobacco Products, emphasized the importance of responsible marketing to prevent youth use. The FDA is committed to monitoring the marketplace and taking necessary actions to protect public health.